BACKGROUND: To investigate the relationship between angiotensinogen (AGT) gene M235T polymorphism and hypertrophic cardiomyopathy (HCM) to explore the potential role of the AGT polymorphism in HCM. METHODS: PubMed, Embase, OVID, Cochrane library, CNKI, Wan Fang Database were searched to identify the studies involving AGT M235T polymorphism and HCM. Two authors performed independent literature review and study quality assessment using the Newcastle-Ottawa Scale (NOS) checklist. A random-effects model was used to calculate the overall combined risk estimates. RESULTS: Nine studies involving 887 cases and 1407 controls were included in our meta-analysis. No significant associations were found between AGT M235T polymorphism and HCM (allele model T vs M: OR = 1.17, 95% CI = 0.95-1.45; dominant model TT vs (MM/MT): OR = 1.21, 95% CI = 1.00-1.45; recessive model (TT/MT) vs MM: OR = 1.12, 95% CI = 0.87-1.45; heterozygous comparison MT vs MM: OR = 1.07, 95% CI = 0.82-1.41; homozygous comparison TT vs MM OR = 1.19, 95% CI = 0.88-1.61. In subgroup analysis, the significant difference of association between AGT M235T polymorphism and HCM existed in Asian and sporadic hypertrophic cardiomyopathy (SHCM), but no significant difference was found in Europeans and familial hypertrophic cardiomyopathy (FHCM). CONCLUSIONS: There is no association between AGT M235T polymorphism and HCM in general populations, but such a relationship exists in Asians and SHCM.
BACKGROUND: To investigate the relationship between angiotensinogen (AGT) gene M235T polymorphism and hypertrophic cardiomyopathy (HCM) to explore the potential role of the AGT polymorphism in HCM. METHODS: PubMed, Embase, OVID, Cochrane library, CNKI, Wan Fang Database were searched to identify the studies involving AGTM235T polymorphism and HCM. Two authors performed independent literature review and study quality assessment using the Newcastle-Ottawa Scale (NOS) checklist. A random-effects model was used to calculate the overall combined risk estimates. RESULTS: Nine studies involving 887 cases and 1407 controls were included in our meta-analysis. No significant associations were found between AGTM235T polymorphism and HCM (allele model T vs M: OR = 1.17, 95% CI = 0.95-1.45; dominant model TT vs (MM/MT): OR = 1.21, 95% CI = 1.00-1.45; recessive model (TT/MT) vs MM: OR = 1.12, 95% CI = 0.87-1.45; heterozygous comparison MT vs MM: OR = 1.07, 95% CI = 0.82-1.41; homozygous comparison TT vs MM OR = 1.19, 95% CI = 0.88-1.61. In subgroup analysis, the significant difference of association between AGTM235T polymorphism and HCM existed in Asian and sporadic hypertrophic cardiomyopathy (SHCM), but no significant difference was found in Europeans and familial hypertrophic cardiomyopathy (FHCM). CONCLUSIONS: There is no association between AGTM235T polymorphism and HCM in general populations, but such a relationship exists in Asians and SHCM.
Authors: X Jeunemaitre; I Inoue; C Williams; A Charru; J Tichet; M Powers; A M Sharma; A P Gimenez-Roqueplo; A Hata; P Corvol; J M Lalouel Journal: Am J Hum Genet Date: 1997-06 Impact factor: 11.025
Authors: R Brugada; W Kelsey; M Lechin; G Zhao; Q T Yu; W Zoghbi; M Quinones; E Elstein; A Omran; H Rakowski; D Wigle; C C Liew; M Sole; R Roberts; A J Marian Journal: J Investig Med Date: 1997-12 Impact factor: 2.895
Authors: Eliecer Coto; María Palacín; María Martín; Mónica G Castro; Julián R Reguero; Cristina García; José R Berrazueta; César Morís; Blanca Morales; Francisco Ortega; Ana I Corao; Marta Díaz; Beatriz Tavira; Victoria Alvarez Journal: J Transl Med Date: 2010-07-01 Impact factor: 5.531